The Role of the Family Practice Provider in the Diagnosis, Management, and Referral Evaluation (ID: i764a-1) Survey

Question Title

* 1. After participating in this activity, how confident are you in the management of patients with AS in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 2. How many years have you been in practice?

>21

11-20

1-10

Question Title

* 3. How many patients with AS do you manage?

1 to 25

26 to 50

51 to 100

100+

I am not directly involved in patient care

Question Title

* 4. Please select the option that best describes your practice setting.

Academic medical center

Community hospital or medical center

VA, DOD or other government

Managed Care

Research

Pharmaceutical industry

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Knowledge of the epidemiology of AS

Knowledge regarding the pathophysiology of AS and role of HLA-B27

Knowledge of the signs and symptoms of AS

Knowledge of the risk factors for AS and progression of the disease

Knowledge of average delays in diagnosis, diagnostic challenges, and the role of the family physician in early detection

An understanding of AS diagnostic considerations, imaging, screening, and when to refer to a rheumatologist

An understanding of AS disease monitoring tools and current guideline recommendations

An understanding of pharmacological treatments for AS, including NSAIDs, TNF-a inhibitors, and IL-17 monoclonal antibodies

Knowledge of outcomes from recent clinical trials, such as the MEASURE trials of secukinumab and COAST trials of ixekizumab

Knowledge of ongoing phase 3 trials for patients with AS

Question Title

* 8. What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please explain)

Question Title

* 9. After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Review the epidemiology, etiology, and signs/symptoms of ankylosing spondylitis	Review the epidemiology, etiology, and signs/symptoms of ankylosing spondylitis Strongly agree	Review the epidemiology, etiology, and signs/symptoms of ankylosing spondylitis Agree	Review the epidemiology, etiology, and signs/symptoms of ankylosing spondylitis Neutral	Review the epidemiology, etiology, and signs/symptoms of ankylosing spondylitis Disagree	Review the epidemiology, etiology, and signs/symptoms of ankylosing spondylitis Strongly disagree
Recognize the role of family practice in the timely diagnosis of AS	Recognize the role of family practice in the timely diagnosis of AS Strongly agree	Recognize the role of family practice in the timely diagnosis of AS Agree	Recognize the role of family practice in the timely diagnosis of AS Neutral	Recognize the role of family practice in the timely diagnosis of AS Disagree	Recognize the role of family practice in the timely diagnosis of AS Strongly disagree
Apply current guideline recommendations to the management of ankylosing spondylitis	Apply current guideline recommendations to the management of ankylosing spondylitis Strongly agree	Apply current guideline recommendations to the management of ankylosing spondylitis Agree	Apply current guideline recommendations to the management of ankylosing spondylitis Neutral	Apply current guideline recommendations to the management of ankylosing spondylitis Disagree	Apply current guideline recommendations to the management of ankylosing spondylitis Strongly disagree
Evaluate the latest data on the efficacy, safety, and dosing/administration of newly-approved biologic therapies for ankylosing spondylitis	Evaluate the latest data on the efficacy, safety, and dosing/administration of newly-approved biologic therapies for ankylosing spondylitis Strongly agree	Evaluate the latest data on the efficacy, safety, and dosing/administration of newly-approved biologic therapies for ankylosing spondylitis Agree	Evaluate the latest data on the efficacy, safety, and dosing/administration of newly-approved biologic therapies for ankylosing spondylitis Neutral	Evaluate the latest data on the efficacy, safety, and dosing/administration of newly-approved biologic therapies for ankylosing spondylitis Disagree	Evaluate the latest data on the efficacy, safety, and dosing/administration of newly-approved biologic therapies for ankylosing spondylitis Strongly disagree

Question Title

* 10. M. Elaine Husni, MD MPH, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 11. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 12. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 13. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for AS or related disease states.

Question Title

* 1. After participating in this activity, how confident are you in the management of patients with AS in your practice?

Question Title

* 2. How many years have you been in practice?

Question Title

* 3. How many patients with AS do you manage?

Question Title

* 4. Please select the option that best describes your practice setting.

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. What barriers do you see to making changes in your practice?

Question Title

* 9. After participating in today’s activity, I am now able to:

Question Title

* 10. M. Elaine Husni, MD MPH, effectively:

Question Title

* 11. The content presented:

Question Title

* 12. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 13. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for AS or related disease states.

Question Title

* 14. If you indicated that you perceived commercial bias or influence, please describe.